A placebo-controlled study of three osteocalcin assays for assessment of prednisolone-induced suppression of bone turnover

Heuck, Carsten; Wolthers, Ole D.

doi:10.1677/joe.0.1590127

Cited by 15 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In adults treated with fluticasone propionate 200 mg or budesonide 400 mg once or twice daily, a suppressive effect has been found on serum osteocalcin, a polypeptide marker for bone formation activity (21)(22)(23). Implications of these preliminary findings, which were not confirmed by a recent study (24), remain obscure.…”

Section: Bone Turnovermentioning

confidence: 87%

“…Implications of these preliminary findings, which were not confirmed by a recent study (24), remain obscure. Osteocalcin assays may give discordant results (22) and the assessment of serum osteocalcin as a marker for osteoporosis risk has not been validated (23). When evaluating the risk, bone density measurements have to be performed during an extended treatment period, i.e.…”

Section: Bone Turnovermentioning

confidence: 99%

See 1 more Smart Citation

Systemic activity versus systemic adverse effects of nasal glucocorticoids in the treatment of allergic rhinitis

Wolthers

2000

SPAE

Self Cite

View full text Add to dashboard Cite

Treatment with nasal glucocorticoids may be associated with systemic activity, which can be detected by sensitive measures of basal adrenal cortisol secretion, bone turnover and short-term growth (knemometry). The detection of systemic activity, however, does not imply that nasal glucocorticoids cause serious adverse systemic effects, such as an inability of the adrenals to react to physiological stress. Studies assessing the ability of the adrenal cortex to react to stimulation have found this to be intact. Long-term assessments of bone density and statural height are needed, and the possibility of additive effects of intranasal glucocorticoids in children receiving concomitant treatment with inhaled glucocorticoids has not yet been studied. Children on long-term treatment with intranasal glucocorticoids should be followed with height measurements every 6 mo.

show abstract

Section: Bone Turnovermentioning

confidence: 87%

Section: Bone Turnovermentioning

confidence: 99%

Systemic activity versus systemic adverse effects of nasal glucocorticoids in the treatment of allergic rhinitis

Wolthers

2000

SPAE

Self Cite

View full text Add to dashboard Cite

show abstract

“…During bone formation, osteoblasts synthesize OSC, which is incorporated into the extracellular bone matrix and a small fraction is released into circulation [72,73]. Serum OSC has demonstrated clinical utility as a biomarker for bone formation both in response to exercise [74] and pharmacological interventions [75]. We hypothesize that Tai Chi will have antiresorptive effects.…”

Section: Methodsmentioning

confidence: 99%

Tai Chi for osteopenic women: design and rationale of a pragmatic randomized controlled trial

Wayne

Buring²,

Davis

et al. 2010

BMC Musculoskelet Disord

View full text Add to dashboard Cite

BackgroundPost-menopausal osteopenic women are at increased risk for skeletal fractures. Current osteopenia treatment guidelines include exercise, however, optimal exercise regimens for attenuating bone mineral density (BMD) loss, or for addressing other fracture-related risk factors (e.g. poor balance, decreased muscle strength) are not well-defined. Tai Chi is an increasingly popular weight bearing mind-body exercise that has been reported to positively impact BMD dynamics and improve postural control, however, current evidence is inconclusive. This study will determine the effectiveness of Tai Chi in reducing rates of bone turnover in post-menopausal osteopenic women, compared with standard care, and will preliminarily explore biomechanical processes that might inform how Tai Chi impacts BMD and associated fracture risks.Methods/DesignA total of 86 post-menopausal women, aged 45-70y, T-score of the hip and/or spine -1.0 and -2.5, have been recruited from primary care clinics of a large healthcare system based in Boston. They have been randomized to a group-based 9-month Tai Chi program plus standard care or to standard care only. A unique aspect of this trial is its pragmatic design, which allows participants randomized to Tai Chi to choose from a pre-screened list of community-based Tai Chi programs. Interviewers masked to participants' treatment group assess outcomes at baseline and 3 and 9 months after randomization. Primary outcomes are serum markers of bone resorption (C-terminal cross linking telopeptide of type I collagen), bone formation (osteocalcin), and BMD of the lumbar spine and proximal femur (dual-energy X-ray absorptiometry). Secondary outcomes include health-related quality-of-life, exercise behavior, and psychological well-being. In addition, kinetic and kinematic characterization of gait, standing, and rising from a chair are assessed in subset of participants (n = 16) to explore the feasibility of modeling skeletal mechanical loads and postural control as mediators of fracture risk.DiscussionResults of this study will provide preliminary evidence regarding the value of Tai Chi as an intervention for decreasing fracture risk in osteopenic women. They will also inform the feasibility, value and potential limitations related to the use of pragmatic designs for the study of Tai Chi and related mind-body exercise. If the results are positive, this will help focus future, more in-depth, research on the most promising potential mechanisms of action identified by this study.Trial registrationThis trial is registered in Clinical Trials.gov, with the ID number of NCT01039012.

show abstract

“…[10][11][12][13] Bone formation is suppressed, as indicated by findings of reduced levels of serum osteocalcin, a polypeptide marker of osteoblast activity. 14,15 This was supported by assessment of formation markers of the most abundant type of collagen in bone, type I collagen, 16,17 i.e., the amino terminal propeptide of type I procollagen (PINP) and the carboxy terminal propeptide of type I procollagen (PICP). Glucocorticoids may initially induce an increase in bone resorption, which is followed by a state of reduced bone resorption.…”

Section: Introductionmentioning

confidence: 97%

Does vitamin D administered to children with asthma treated with inhaled glucocorticoids affect short‐term growth or bone turnover?

Schou¹,

Heuck²,

Wolthers

2003

Pediatric Pulmonology

View full text Add to dashboard Cite

Our objective was to assess whether administration of 25-OH-vitamin D to children with asthma treated with inhaled dry-powder budesonide 400 microg daily affects short-term growth or markers of bone turnover. We utilized a randomized, double-blind, two-period crossover trial with run-in and washout periods of 2 weeks and treatment periods of 4 weeks duration. The setting was an Outpatient clinic in a secondary referral center. Subjects included 14 boys and 3 girls with a mean age of 11.7 (range, 6.1-14.4) years. Interventions included 15 microg (600 IU) 25-OH-vitamin D (cholecalciferol) in one tablet ABCDin(R) once daily in the morning. Primary outcome measures were: lower leg growth rate, serum osteocalcin, and serum markers of type I collagen turnover, i.e., the amino terminal propeptide of type I procollagen (PINP), the carboxy terminal propeptide of type I procollagen (PICP) (formation markers), and the carboxy terminal pyridinoline cross-linked telopeptide of type I collagen (ICTP) (degradation markers). Secondary outcome measures were parameters of asthma control and serum 25-OH-vitamin D. Lower leg growth rate was 0.22 mm/week during vitamin D and 0.25 mm/week during placebo treatment (NS). Osteocalcin was 59.9 and 57.8 microg/l during vitamin D and placebo treatment, respectively, PINP 574 and 565 microg/l, PICP 381 and 382 microg/l, and ICTP 11.5 and 11.1 microg/l, respectively (NS). Serum 25-OH-vitamin D was 76.3 nmol/l and 48.2 nmol/l, respectively (P < 0.001). There were no statistically significant differences in measures of pulmonary function. In conclusion, administration of 25-OH-vitamin D does not affect short-term growth or markers of bone turnover in children with asthma treated with inhaled dry-powder budesonide 400 microg daily.

show abstract

A placebo-controlled study of three osteocalcin assays for assessment of prednisolone-induced suppression of bone turnover

Cited by 15 publications

References 24 publications

Systemic activity versus systemic adverse effects of nasal glucocorticoids in the treatment of allergic rhinitis

Systemic activity versus systemic adverse effects of nasal glucocorticoids in the treatment of allergic rhinitis

Tai Chi for osteopenic women: design and rationale of a pragmatic randomized controlled trial

Does vitamin D administered to children with asthma treated with inhaled glucocorticoids affect short‐term growth or bone turnover?

Contact Info

Product

Resources

About